Skip to main content
. 2016 Dec 29;8(6):10114–10135. doi: 10.18632/oncotarget.14357

Figure 6. IRISOE promotes formation of TIC tumors, their dissemination and metastasis.

Figure 6

A. Luciferase signals obtained in tumors developed using different concentration of parental or IRISOE MCF7 at week 8 post cells injection. B. Slopes of curves generated for luciferase signals for tumors developed using MCF7/IRISOE cells originally injected at the indicted numbers plotted against time (weeks). C. Real time QRT/PCR analysis for human Sox2 and Oct4 mRNAs expression in tumors developed using MCF7/IRISOE cells originally injected at the indicated numbers at week 8. D. Assessment of the stemness enhancement factor in tumors developed using MCF7/IRISOE originally injected at the indicated numbers extrapolated from the data presented in (C). RT/PCR analysis for human IRIS mRNA (upper) or mouse GAPDH mRNA (loading control, lower) in PB E. or BM F. samples from mice originally injected with the indicated cell lines at the indicated numbers. G. Association between IRIS mRNA expression and the expression of the dissemination biomarkers; CK19, MGA, PIP, hGC mRNAs in a cohort of metastatic breast cancer patients (n=66, from Egyptian NCI) conducted using real-time QRT/PCR. H. Schematic presentation of our overall hypothesis that bidirectional interactions with the microenvironment enhance IRISOE/TNBC/TIC early lesion formation, aggressiveness, and eventually dissemination and metastasis.